News
New insight into sensing and function of the bacterial lysate OM-85
Bacterial lysates are widely used in the clinic to minimize the pathologic consequences of respiratory infections. Our new study shows how one such lysate, OM-85, works on human myeloid cells to trigg...
Prestigious international award to Prof. Franco Cavalli
The American Association for Cancer Research (AACR) will present the prestigious "Award for Lifetime Achievement" to Prof. Franco Cavalli during the opening ceremony of their annual meeting on Sunday,...
Drug resistance: identified a new key mechanism in the treatment of B-cell lymphomas
The Lymphoma Genomics Laboratory, directed by Prof. Francesco Bertoni at the Institute of Oncology Research (IOR, affiliated to USI and member of Bios+), identified a new mechanism behind the resistan...
A painkiller cell
Control of localized pain syndrome by autologous fat graft. The abundance of a particular subset of mesenchymal stem cells in the adipose tissue grafted into scars correlates with pain reduction....
Prostate cancer: IOR contributes to significant advancement
The Molecular Oncology research group, led by Prof. Andrea Alimonti at the Institute of Oncology Research (IOR, affiliated to USI and member of Bios+), in close collaboration with the team of Pro...
Two is better than one against tick viruses
Ticks can transmit viruses that can cause brain infection requiring hospitalization. New work shows that one such viruses, named TBEV, rapidly develops resistance to treatment, but this can be overcom...
Prof. Andrea Alimonti awarded prestigious SNSF Advanced Grant
Prof. Andrea Alimonti and his team have been awarded the SNSF Advanced Grant 2022, a prestigious funding designed to support innovative, high-risk research in Switzerland. Due to Switzerland's status...
Bios+ hosted the Diplomacy Day in collaboration with the Locarno Film Festival
The Institute for Research in Biomedicine (IRB) and the Institute of Oncology Research (IOR), in collaboration with the Locarno Film Festival and the City of Bellinzona, proudly announce the successfu...
IOR: promising breakthrough in prostate cancer therapy
The Molecular Oncology research group, led by Prof. Andrea Alimonti at the Institute of Oncology Research (IOR, affiliated to USI and member of Bios+), has discovered that prostate cancer cells h...
New strategic infectious disease research collaboration between the IRB and The Rockefeller University
The Institute for Research in Biomedicine (IRB) in Bellinzona and The Rockefeller University in New York announced the beginning of an important strategic collaboration to advance infectious disease r...
Bios+: Professor Franco Cavalli appointed president
The Bellinzona Institutes of Science (Bios+) association composed of two members - the Institute for Research in Biomedicine (IRB) and the Oncology Research Institute (IOR), affiliated to the Universi...
A new Research Group at the IRB led by Dr. Caroline Junqueira
It is now official: Caroline Junqueira, PhD, will join the Institute for Research in Biomedicine (IRB) starting August 1, 2023. With her arrival, the IRB will have a new Group Leader who will develop ...
New IRB study: finding on the influence of Myc in NK cells
This collaborative study, mainly centered at Bios+ (Bellinzona Institutes of Science), reveals the importance of the transcription factor and proto-oncogene Myc in maintaining Natural Killer (NK) cell...
IOR: Andrea Alimonti appointed as new Director
Researchers at the Institute of oncology research (IOR, affiliated to USI and member of Bios+), in collaboration with researchers from the University of Padova, have made a groundbreaking di...
More than 150 participants at the Castelgrande Lecture with Prof. Alberto Mantovani
A resounding success." This is how one can sum up the public event staged last Wednesday, May 3, in Bellinzona that was attended by more than 150 people, including experts in the field and members of ...
‘Good autoantibodies’ could help against long Covid
In Covid-19 disease, antibodies against the coronavirus protect, while those that attack ourselves (autoantibodies, precisely) are harmful. Unexpectedly, a new class of ‘good autoantibodie...
Important discovery at the IOR
Researchers at the Institute of oncology research (IOR, affiliated to USI and member of Bios+), in collaboration with researchers from the University of Padova, have made a groundbreaking di...
Antibodies against coronaviruses coldspots discovered
Can one single antibody catch them all? Scientists discover antibodies that recognise all SARS-CoV-2 variants and also other coronaviruses that cause human disease. The finding opens the d...
Pfizer Research Award, IRB and IOR researchers among winners
The Pfizer Prize Foundation awarded 11 studies and 21 researchers, including Dr Nicolò Pernigoni, Dr Elena Zagato and Professor Arianna Calcinotto of the Oncology Research Institute (IOR) and Dr Ferna...
New discovery at the IOR for the treatment of hepatic disorders of abnormal lipid deposition
The Experimental Therapeutics group, directed by Prof. Carlo V. Catapano at the Institute of Oncology Research (IOR, affiliated to USI and member of Bios+), in collaboration with Prof. ...
Action of mismatch repair and WRN proteins on cruciform DNA
Cancers arise due to a broad spectrum of mutations and hence have very different genetic makeups. Efforts to develop more targeted or personalized therapies rely on potential vulnerabilities of cancer...
Clonal composition and persistence of antigen-specific T follicular helper cells
The Sallusto group (ETH IMBB and IRB Bellinzona) published a paper in the European Journal of Immunology providing insights on the relationship of human T follicular helper cells in blood (cTfh cells)...
DNA protection: new IRB Study
The BRCA2 gene is mutated in many familial and sporadic breast and ovarian cancers, making it an important cancer suppressor. BRCA2 has been long known to function together with RAD51 in DNA break rep...
Doctor Honoris Causa title conferred on Prof. Federica Sallusto
Bellinzona, Nov. 17, 2022 – During the Dies Academicus, the University of Fribourg conferred to Prof. Federica Sallusto the title Doctor honoris causa (Dr. h. c.) for her excellence in scientific and ...
Secretory IgA promotes gut fitness
Secretory Immunoglobulin A (SIgA) is the antibody produced within mucosal membranes and is the most abundant antibody type synthesized in our body. In the intestine, SIgA possesses two antithetic func...
Melanoma metastasis: new IRB study
Melanoma is the most lethal skin cancer, and its incidence, though low, has steadily increased over the last few years. During melanoma progression, tumor cells spread across the body via the lymphati...
Opening for Group Leader position at the IRB
The Institute for Research in Biomedicine (IRB) officially opened an international call for the recruitment of a new group leader (deadline December 1, 2022). We seek an outstanding scientist to comp...
Bios+: Open Day under the banner of Science and curiosity
Recent years have generated considerable demand for information and interaction between Science and society. In this sense, the open day organized in the new Bios+ building in Bellinzona by IRB, IOR...
A new research group at the IOR
On 1 September 2022, a new research group led by Dr Arianna Baggiolini began its activities at the Institute of Oncology Research (IOR) in Bellinzona. This makes six groups in the research programme d...
Also dogs develop malignant lymphoma
A study conducted by scientists at the Institute of Oncology Research (IOR, affiliated with USI and a member of Bios+) in collaboration with researchers specialized in veterinary oncology at the Unive...
Bios+: Nearly 1’000 visitors to the Bellinzona Research Institutes' Open day
On Saturday, May 14, the Institute for Research in Biomedicine (IRB), the Institute of Oncology Research (IOR) and the Laboratories for Translational Research of the EOC opened the doors of the new Bi...
Lymphomas: new model developed at the IOR against drug resistance
The Lymphoma Genomics group, directed by Prof. Francesco Bertoni at the Institute of Oncology Research (IOR, affiliated to USI and member of Bios+), identified a new mechanism behind the resistance to...
Breakthroughs at IOR in the research for anti-metastatic therapies
The Molecular Oncology research group lead by Prof. Andrea Alimonti at the Istitute of Oncology Research (IOR, affiliated to USI and member of Bios+) has identified, through the use of bioinform...
Francesco Bertoni has been elected as President of the Lymphoma Project Group of Swiss Group for Clinical Cancer Research
Lymphomas have always been a main focus for the Institute of Oncology Research (IOR) and the Oncology Institute of Southern Switzerland (IOSI - EOC). After many years dedicated to lymphoma research, B...
The Swiss Institute of Bioinformatics renews Luciano Cascione's mandate as SIB Group leader at the IOR
The SIB Swiss Institute of Bioinformatics is an internationally recognized non-profit organization dedicated to biological and biomedical data science. It is present in the main academic institutions ...
IOR publication on cancer among the "Top 10" in Europe
The EACR European Association for Cancer Research has included a publication of the Institute of Oncology Research (IOR, affiliated to USI) in its "Top 10 Cancer Research Publications", which ranks th...
Pfizer Research Prize in Oncology for research performed at IOR
The awards for the 31st Pfizer Prize for Research were given on Thursday, February 10th, in Zurich. Among the winners of the Oncology category were Ilaria Guccini and Ajinkya Revandka, former research...
IOR and IOSI gold medal in lymphomas
The New England Journal of Medicine (NEJM), the world's leading medical journal, has entrusted the lymphoma group of the Institute of Oncological Research (IOR, affiliated to USI and member of Bios+) ...
IOR researchers develops a novel method to track precisely prostate cancer progression
In the fight against tumours, how the key driver mutations related to disease progression and metastatic spread regulate gene expression to promote ultimately tumor progression and cancer cell adaptat...
VIDEO RECORDING of the new building inauguration (27.11.2021)
Watch the recap video: Watch the complete video recording: ...
Roger Geiger selected to the EMBO Young Investigator programme
The European Molecular Biology Organisation (EMBO) has selected Roger Geiger, group leader at the Institute for Research in Biomedicine (IRB, affiliated to USI Università della Svizzera...
Interplay of Dna2 and RPA in DNA metabolism, a Nature Communications paper
DNA end resection is required for accurate processing of broken DNA. In a paper published in Nature Communications, IRB researchers Acharya, Cejka and colleagues investigated the interplay o...
Krebsliga awards the Robert Wenner prize to Davide Rossi at IOR
Swiss Cancer League - Krebsliga - has awarded the 2019 Robert Wenner Prize for young cancer researchers to Davide Rossi, Group leader at the Institute of Oncology Research (IOR, affiliated to Universi...
Inaugurata la nuova sede degli Istituti di ricerca scientifica IRB, IOR e EOC
Oltre 250 le persone presenti alla cerimonia del nuovo stabile di proprietà della Fondazione IRB Si è tenuta oggi la cerimonia d’inaugurazione ufficiale della nuova sede degli Istituti di ricerca s...
A "jubilee grant" of the Helmut Horten Foundation awarded for research against lymphoma
On October 22, 2021, the Helmut Horten Foundation celebrated its 50th anniversary with a ceremony held at ETH Zurich. On this occasion, researchersDavide Rossiat the Institute of Oncology Research (IO...
Intestinal bacteria mechanism discovered at the IOR that could improve prostate cancer therapy
Scientists at the Institute of Oncology Research (IOR, affiliated to USI) and The Institute of Cancer Research, London, in collaboration with researchers from the University of Padova, have made a ver...
Engineered bacteria for cancer immunotherapy
A Nature paper by theSystems Immunologygroup, headed byRoger Geiger, at the Institute for Research in Biomedicine (IRB, affiliated to USI). This study describes an innovative strategy to improve the ...
New SNSF grants awarded to three IRB researchers
The Swiss National Science Foundation (SNSF) has recently awarded three group leaders at the Institute for Research in Biomedicine (IRB, affiliated to USI): Silvia Monticelli, Santiago González and Pe...
First peptide inhibitor of the CXCL12/HMGB1 heterocomplex identified
During inflammatory reactions, the production and release of chemotactic factors guide the recruitment of selective leukocyte subpopulations. The chemokine CXCL12 and the alarmin HMGB1, both released ...
IRB ready for clinical testing of second generation antibody against COVID-19
Following the development of a second-generation antibody against the novel coronavirus (SARS-CoV-2) and its variants, the Institute for Research in Biomedicine (IRB, affiliated to USI) is now mo...
